{
    "organizations": [],
    "uuid": "541a83fae779a12c6835215ff5fe10a80382ee4a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-roche-says-fda-grants-priority-rev/brief-roche-says-fda-grants-priority-review-for-mabthera-rituxan-for-pemphigus-vulgaris-idUSFWN1Q31GI",
    "ord_in_thread": 0,
    "title": "BRIEF-Roche says FDA Grants Priority Review For Mabthera/ Rituxan For Pemphigus Vulgaris",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - Roche Holding AG:\n* ROCHE HOLDING AG - FDA GRANTS PRIORITY REVIEW FOR ROCHEâ€™S MABTHERA/ RITUXAN (RITUXIMAB) FOR PEMPHIGUS VULGARIS Source text for Eikon: Further company coverage: (Reporting By Michael Shields)\n ",
    "published": "2018-02-14T14:16:00.000+02:00",
    "crawled": "2018-02-15T20:56:34.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "roche",
        "holding",
        "ag",
        "roche",
        "holding",
        "ag",
        "fda",
        "grant",
        "priority",
        "review",
        "roche",
        "rituxan",
        "rituximab",
        "pemphigus",
        "vulgaris",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "michael",
        "shield"
    ]
}